Abstract 1021
Background
Induction chemotherapy (IC) often compromises the compliance of following chemoradiotherapy (CRT) in LA-SCCHN. In particular, impaired compliance of cisplatin (CDDP) during CRT negatively affects outcomes. Here, we aimed to assess the feasibility and efficacy of paclitaxel (PTX), carboplatin (CBDCA), and cetuximab (Cmab) as IC for unresectable LA-SCCHN.
Methods
Patients with biopsy-proven, unresectable LA-SCCHN were enrolled. IC consisted of CBDCA AUC = 1.5, PTX 80mg/m2 and Cmab with an initial dose of 400mg/m2 followed by 250mg/m2 administered weekly for 8 weeks. Following IC, CDDP (20mg/m2, 4 days x 3 cycles) and concurrent radiotherapy (70Gy/35fr) were started. Primary endpoint was the rate of CRT completion, defined by (1) completion of planned CDDP relative dose intensity (RDI) ≥ 80%, and (2) completion of radiotherapy within 2 weeks after planned completion date. PCE was planned to be deemed effective if the Bayesian posterior probability (PP) that the rate of CRT completion was > 65% exceeded 84%.
Results
35 patients were eligible and received study treatment. Cases were hypopharynx/oropharynx/larynx in 17/17/1 patients, all Stage IV (stage IVA: 24, stage IVB: 11). Of 35 patients, 34 (97%) completed IC and 32 received CRT (FAS). Of 32 FAS cases, the rate of CRT completion was 96.9%, and the study’s primary endpoint was therefore met (PP = 99.9% > 84%). Mean cumulative dose and RDI of CDDP in CRT was 232.5mg (160-240mg) and 100% (66.7-100%), respectively. Response rate was 88.6% in the IC phase and 93.8% in the CRT phase. 2-year rates of local progression, distant metastasis, event-free survival and overall survival were 34.9%, 16.7%, 55.1% and 83.5%, respectively. Main grade 3 toxicities included neutropenia (11%), skin rash (6%), and anemia (6%) in the IC phase; and oral mucositis (31%), neutropenia (13%), and radiation dermatitis (13%) in the CRT phase. No grade 4 toxicity or treatment-related death was seen.
Conclusions
PCE as IC was feasible, with promising efficacy and no effect on compliance of following CRT in unresectable LA-SCCHN. A Phase III comparison with CRT alone is warranted.
Clinical trial identification
UMIN000014430.
Legal entity responsible for the study
IC-PCE Study Executive Committee.
Funding
National Cancer Center Research and Development Fund (25-B-2).
Editorial Acknowledgement
Disclosure
K. Okami: Honoraria: Merck Serono Co, Ltd; Consulting or advisory role: Merck Serono Co, Ltd. S. Minami: Speakers’ bureau: Nihon Cochlear; Research funding: Taiho Pharmaceutical, Kyorin Pharmaceutical. S. Iwae: Research funding: Ono Pharmaceutical CO, Ltd, Otsuka Pharmaceutical CO, Ltd. S. Nomura: Employment: Asahi Kasei Pharma (Immediate Family Member). S. Okano: Honoraria: Merck Serono, Brystol-Myers Squibb, Ono Pharmaceutical Co, Nippon Kayaku Co. M. Tahara: Honoraria: Bristol-Myers Squibb, Ono Pharmaceutical CO, Ltd, Merck Serono Co, Ltd, Eisai Co, Ltd, AstraZeneca PLC. All other authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract